<DOC>
	<DOCNO>NCT01978093</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity GSK Biologicals ' Hib-MenCY-TT ( MenHibrix® ) vaccine co-administered Rotarix , Prevnar 13 Havrix compare PedvaxHIB co-administered Rotarix , Prevnar 13 Havrix infant toddler .</brief_summary>
	<brief_title>Immunogenicity , Safety Reactogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' Hib-MenCY-TT ( MenHibrix® ) Vaccine Compared Merck &amp; Co , Inc. PedvaxHIB Vaccine Healthy Infants Toddlers 12 15 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol . A male female , include , 6 12 week age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Born fullterm ( i.e . born gestation period least 37 week inclusive ) . Infants receive previous dose hepatitis B vaccine receive 1 dose hepatitis B vaccine administer least 30 day prior enrollment . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth prior first vaccine dose . Inhaled topical steroid allow . Previous vaccination Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , rotavirus , pneumococcus , hepatitis A and/or poliovirus ; one previous dose hepatitis B vaccine . Planned administration/administration vaccine foreseen study protocol period start 30 day end 30 day dose vaccine . Subjects may receive inactivated influenza vaccine pandemic influenza vaccine time study accord national recommendation . Measles , mumps , rubella varicella vaccination allow 30 day 30 day final vaccination HibMenCYTT PedvaxHIB . History Neisseria meningitidis , Haemophilus influenzae type b , diphtheria , tetanus , pertussis , pneumococcus , hepatitis B , hepatitis A , rotavirus , and/or poliovirus disease . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine , include dry natural latex rubber . Hypersensitivity component vaccine , include gelatin neomycin . Major congenital defect serious chronic illness . History neurologic disorder seizure . A single , simple febrile seizure allow . Subjects history intussusception uncorrected congenital malformation gastrointestinal tract would predispose intussusception . Acute disease and/or fever time enrollment . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Conjugate</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Hib-MenCY-TT vaccine</keyword>
	<keyword>Haemophilus type b</keyword>
	<keyword>Safety</keyword>
	<keyword>Reactogenicity</keyword>
</DOC>